A pilot study of primary temozolomide chemotherapy and deferred radiotherapy in elderly patients with glioblastoma
A pilot study of primary temozolomide chemotherapy and deferred radiotherapy in elderly patients with glioblastoma
复制标题
DOI：
10.1007/s11060-006-9269-z
复制
发表时间：
2007-03
影响因子：
3.9
通讯作者：
M. Chamberlain;L. Chalmers
中科院分区：
文献类型：
--
作者：
M. Chamberlain;L. Chalmers
对于新诊断的胶质母细胞瘤（GBM）老年患者（年龄≥ 70岁），尚无标准治疗。在15例连续接受替莫唑胺（TMZ）治疗的患者（中位年龄79岁）（治疗42天;停药14天）中，中位生存期为6个月（范围4-14个月）。这项初步研究表明，低剂量每日TMZ可能是一种替代和同等有效的治疗更传统的管理放射治疗。
There is no standard of care for elderly patients (age ≥ 70 years) with newly diagnosed glioblastoma (GBM). In 15 consecutive patients (median age 79 years) treated with temozolomide (TMZ) (42 days on; 14 days off), median survival was 6 months (range 4–14 months). This pilot study suggests that low dose daily TMZ may represent an alternative and equally effective treatment to more traditionally administered radiotherapy.